Histidine copolymer and methods for using same

• US 7,163,695 B2
• Filed: 12/20/2000
• Issued: 01/16/2007
• Est. Priority Date: 12/29/1999
• Status: Active Grant

• Current Assignee: Mixson A. James
• Original Assignee: Mixson A. James
• Inventors: Mixson, A. James
• Primary Examiner(s): PRIEBE, SCOTT DAVID
• Application Number:
  US10/018,103
• Publication Number:
  US 20030045465A1
• Time in Patent Office: 2,218 Days
• Field of Search: None
• US Class Current: 424/486
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.

Claims

1. A pharmaceutical agent delivery composition comprising:

(a) a transport polymer comprising a peptide, characterized as having at least 10 amino acid residues, and wherein at least 10% of said amino acid residues are histidine, and wherein at least 10% of said amino acid residues are selected from the group consisting of non-histidine amino acids with a side-group that carries a positive charge at physiological pH, and wherein the molecular structure of said peptide is selected from the group consisting of;

linear, with the proviso that said peptide does not comprise a hexa-peptide having the sequence His-His-His-His-His-His, unless at least 10% of the remaining amino acid residues of said peptide are histidine; and

branched, with a backbone peptide of 1 or more amino acid residues and at least one peptide branch of 1 or more amino acid residues covalently attached to a side-group of an amino acid residue of said backbone peptide, with the proviso that each peptide branch can consist of a single histidine residue only if the backbone peptide does not consist solely of lysine residues;

 

with the proviso that said transport polymer does not consist of;

a random histidine copolymer;

or

a block copolymer of histidine and a non-histidine amino acid with a side-group that carries a positive charge at physiological pH;

(b) a pharmaceutical agent associated with said transport polymer; and

(c) optionally, at least one intracellular delivery component associated with said transport polymer and/or said pharmaceutical agent.

2. The pharmaceutical agent delivery composition of claim 1, wherein at least 20% of the amino acid residues of said peptide are histidine, and wherein at least 20% of said amino acid residues are selected from the group consisting of non-histidine amino acids with a side-group that carries a positive charge at physiological pH.

3. The pharmaceutical agent delivery composition of claim 2, wherein about 40% to about 60% of the amino acid residues of said peptide are histidine.

4. The pharmaceutical agent delivery composition of claim 2, wherein said peptide comprises a subsegment of amino acid residues selected from the group consisting of:

K-H-K-H-K-H-K-H-K-H (SEQ ID NO;

     14),

K-H-K-H-K-H-K-G-K-H-K-H-K (SEQ ID NO;

1),

K-H-K-H-K-H-K-G-K-H-K-H-K-H-K (SEQ ID NO;

2),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

3),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

4),

K-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-K (SEQ ID NO;

5),

K-K-H-H-H-K-H-H-H-K-K-H-H-H-K-H-H-H-K-K (SEQ ID NO;

6),

H-H-K-H-H-K-H-H-K-H-H-K-H-H-K (SEQ ID NO;

15),

K-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-K (SEQ ID NO;

16),

end-to-end repeats of one or more of the above sequences, and

the reverse of any of the above sequences.

5. The pharmaceutical agent delivery composition of claim 2, further comprising at least one intracellular delivery component associated with said transport polymer and/or said pharmaceutical agent.

6. The pharmaceutical agent delivery composition of claim 5, wherein said intracellular delivery component comprises a lipid.

7. The pharmaceutical agent delivery composition of claim 2, further comprising a transition metal.

8. The pharmaceutical agent delivery composition of claim 2, wherein said pharmaceutical agent consists of at least one therapeutic agent.

9. The pharmaceutical agent delivery composition of claim 8, wherein said therapeutic agent is selected from the group consisting of a protein, an oligopeptide, a nucleic acid, a cancer chemotherapeutic agent, an infectious disease chemotherapeutic agent, and any combination of two or more of the above.

10. The pharmaceutical agent delivery composition of claim 9, wherein said therapeutic agent is nucleic acid.

11. The pharmaceutical agent delivery composition of claim 10, wherein said nucleic acid is an antisense oligonucleotide, a ribozyme, an RNA-cleaving DNA oligonucleotide, or a combination of two or more of the above.

12. The pharmaceutical agent delivery composition of claim 10, wherein at least about 40% of the amino acid residues of said peptide are histidine.

13. The pharmaceutical agent delivery composition of claim 12, wherein said pharmaceutical agent delivery composition further comprises an intracellular delivery component.

14. The pharmaceutical agent delivery composition of claim 13, wherein about 40% to about 60% of the amino acid residues of said peptide are histidine.

15. A method for delivering a pharmaceutical agent to the interior of a cell, said method comprising a step of contacting the cell with the pharmaceutical agent delivery composition of claim 1.

16. The method of claim 15, wherein at least 20% of the amino acids of said peptide are histidine and at least 20% of the non-histidine amino acid residues of said peptide carry a positive charge at physiological pH.

17. The method of claim 16, wherein the molecular structure of said peptide is branched.

18. The method of claim 16, wherein said peptide comprises a subsegment of amino acid residues selected from the group consisting of:

K-H-K-H-K-H-K-H-K-H (SEQ ID NO;

     14),

K-H-K-H-K-H-K-G-K-H-K-H-K (SEQ ID NO;

1),

K-H-K-H-K-H-K-G-K-H-K-H-K-H-K (SEQ ID NO;

2),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

3),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

4),

K-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-K (SEQ ID NO;

5),

K-K-H-H-H-K-H-H-H-K-K-H-H-H-K-H-H-H-K-K (SEQ ID NO;

6),

H-H-K-H-H-K-H-H-K-H-H-K-H-H-K (SEQ ID NO;

15),

K-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-K (SEQ ID NO;

16),

end-to-end repeats of one or more of the above sequences, and

the reverse of any of the above sequences.

19. The method of claim 16, wherein said pharmaceutical agent delivery composition further comprises at least one intracellular delivery component associated with said transport polymer and/or said pharmaceutical agent.

20. The method of claim 19, wherein said intracellular delivery component comprises a lipid.

21. The method of claim 16, wherein said pharmaceutical agent delivery composition further comprises a transition metal.

22. The method of claim 16, wherein about 40% to about 60% of the amino acids of said peptide are histidine.

23. The method of claim 16, wherein said pharmaceutical agent consists of at least one therapeutic agent.

24. The method of claim 23, wherein said therapeutic agent is selected from the group consisting of a protein, an oligopeptide, a nucleic acid, a cancer chemotherapeutic agent, an infectious disease chemotherapeutic agent, and any combination of two or more of the above.

25. The method of claim 24, wherein said therapeutic agent is nucleic acid.

26. The method of claim 25, wherein said nucleic acid is an antisense oligonucleotide, a ribozyme, an RNA-cleaving DNA oligonucleotide, or a combination of two or more of the above.

27. The method of claim 16, further comprising the steps of:

removing said cell from a subject prior to contacting said cell with said pharmaceutical agent delivery composition; and

administering said cell to said subject after contacting said cell with said pharmaceutical agent delivery composition.

28. The method of claim 27, wherein said pharmaceutical agent delivery composition further comprises an intracellular delivery component.

29. A method for producing a pharmaceutical agent delivery composition comprising the steps of:

a. providing a transport polymer comprising a peptide characterized as having at least 10 amino acid residues, and wherein at least 10% of said amino acid residues are histidine, and wherein at least 10% of said amino acid residues are selected from the group consisting of non-histidine amino acids with a side-group that carries a positive charge at physiological pH, and wherein the molecular structure of said peptide is selected from the group consisting of;

linear, with the proviso that said peptide does not comprise a sequence His-His-His-His-His-His, unless at least 10% of the remaining amino acid residues of said peptide are histidine; and

branched, with a backbone peptide of 1 or more amino acid residues and at least one peptide branch of 1 or more amino acid residues covalently attached to a side-group of an amino acid residue of said backbone peptide, with the proviso that each peptide branch can consist of a single histidine residue only if the backbone peptide does not consist solely of lysine residues;

with the proviso that said transport polymer does not consist of;

a random histidine copolymer;

or

a block copolymer of histidine and a non-histidine amino acid with a side-group that carries a positive charge at physiological pH;

b. providing a pharmaceutical agent capable of associating with said transport polymer;

c. combining said transport polymer with said pharmaceutical agent to form a polymer/pharmaceutical agent complex; and

d. mixing said complex with an intracellular delivery component.

30. The method of claim 29, wherein said intracellular delivery component comprises a lipid.

31. A pharmaceutical agent delivery composition comprising:

(a) a pharmaceutical agent;

(b) a transport polymer in association with the pharmaceutical agent, the transport polymer comprising a peptide characterized as having at least 10% of the amino acid residues are histidine and at least 10% of the amino acid residues are non-histidine, wherein the non-histidine residues are selected so as to tailor the transport polymer to the pharmaceutical agent and a method of association between the pharmaceutical agent and the transport polymer, and wherein the molecular structure of the peptide is selected from the group consisting of;

linear and having at least 13 amino acids, with the proviso that;

a. the entire sequence of said peptide cannot be described by the formula;

(XHHX)_n, wherein H is histidine, X is a hydrophobic amino acid, and n is an integer greater than or equal to 4;

b. the entire sequence of said peptide cannot be described by the formula;

(XHXH)_n, wherein H is histidine, X is a hydrophobic amino acid, and n is an integer greater than or equal to 4; and

c. said peptide does not comprise a hexa-peptide having the sequence His-His-His-His-His-His, unless at least 10% of the remaining amino acid residues of said peptide are histidine; and

branched and having at least 40 amino acids, with a backbone of 1 or more amino acid residues and at least one branch of 1 or more amino acid residues covalently attached to a side-group of an amino acid residue of said backbone, with the proviso that each branch can consist of a single histidine residue only if the backbone does not consist solely of lysine residues;

 

with the proviso that said transport polymer does not consist of;

a random histidine copolymer;

or

a block copolymer of histidine and a non-histidine amino acid with a side-group that carries a positive charge at physiological pH; and

(c) optionally, at least one intracellular delivery component associated with said transport polymer and/or said pharmaceutical agent.

32. The pharmaceutical agent delivery composition of claim 31, further comprising a transition metal.

33. The pharmaceutical agent delivery composition of claim 31, wherein the pharmaceutical agent has an overall net negative charge, wherein at least 20% of the amino acid residues of said peptide are histidine, and wherein at least 20% of said amino acid residues are selected from the group consisting of non-histidine amino acids with a side-group that carries a positive charge at physiological pH.

34. The pharmaceutical agent delivery composition of claim 33, wherein about 40% to about 60% of the amino acids of said peptide are histidine.

35. The pharmaceutical agent delivery composition of claim 33, wherein the pharmaceutical agent comprises nucleic acid and wherein about 40% to about 60% of said amino acid residues of said peptide are histidine.

36. The pharmaceutical agent delivery composition of claim 35, wherein the non-histidine residues are each independently selected from the group consisting of lysine and glycine.

37. The pharmaceutical agent delivery composition of claim 35, wherein the molecular structure of the peptide is branched.

38. The pharmaceutical agent delivery composition of claim 35, wherein said peptide is selected from the group consisting of linear and having less than about 50 amino acids, and branched and having less than about 300 amino acids.

39. The pharmaceutical agent delivery composition of claim 35, further comprising at least one intracellular delivery component.

40. The pharmaceutical agent delivery composition of claim 39, wherein the intracellular delivery component comprises a lipid.

41. The pharmaceutical agent delivery composition of claim 40, wherein the lipid is a cationic lipid.

42. The pharmaceutical agent delivery composition of claim 40, wherein the molecular structure of the peptide is linear.

43. The pharmaceutical agent delivery composition of claim 33, wherein the pharmaceutical agent comprises a therapeutic agent selected from the group consisting of an antisense oligonucleotide, a ribozyme, an RNA-cleaving DNA oligonucleotide, an expression vector, and a combination of two or more of the above.

44. The pharmaceutical agent delivery composition of claim 43, wherein the therapeutic agent is an RNA-cleaving DNA oligonucleotide which targets VEGF receptor mRNA.

45. The pharmaceutical agent delivery composition of claim 33, wherein said peptide comprises a segment of amino acid residues selected from the group consisting of:

K-H-K-H-K-H-K-H-K-H (SEQ ID NO;

     14),

K-H-K-H-K-H-K-G-K-H-K-H-K (SEQ ID NO;

1),

K-H-K-H-K-H-K-G-K-H-K-H-K-H-K (SEQ ID NO;

2),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

3),

K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K (SEQ ID NO;

4),

K-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-H-K-H-K (SEQ ID NO;

5),

K-K-H-H-H-K-H-H-H-K-K-H-H-H-K-H-H-H-K-K (SEQ ID NO;

6),

H-H-K-H-H-K-H-H-K-H-H-K-H-H-K (SEQ ID NO;

15),

K-K-H-K-H-K-H-K-H-K-G-K-H-K-H-K-H-K-H-K-K (SEQ ID NO;

16),

end-to-end repeats of one or more of the above sequences, and the reverse of any of the above sequences.

46. A method for delivering a pharmaceutical agent to the interior of a cell, said method comprising a step of contacting the cell with the pharmaceutical agent delivery composition of claim 31.

47. The method of claim 46, wherein the pharmaceutical agent has an overall net negative charge, wherein at least 20% of the amino acid residues of said peptide are histidine, and wherein at least 20% of said amino acid residues are selected from the group consisting of non-histidine amino acids with a side-group that carries a positive charge at physiological pH.

48. The method of claim 47, wherein the pharmaceutical agent comprises nucleic acid and wherein about 40% to about 60% of said amino acid residues of said peptide are histidine.

49. The method of claim 48, wherein the non-histidine residues are each independently selected from the group consisting of lysine and glycine.

50. The method of claim 47, wherein the pharmaceutical agent delivery composition further comprises at least one intracellular delivery component, wherein the intracellular delivery component comprises a cationic lipid.

51. The method of claim 47, wherein about 40% to about 60% of the amino acids of said peptide are histidine.